The abstract submission deadline for the 21st Annual Meeting of the Translational Research Cancer Centers Consortium has been extended to January 20. The WVU Cancer Institute is the organizing center of this year’s meeting titled Out of the Valley: Moving Mountains for the Immunotherapy of Cancer and scheduled for February 14-16, 2018, at Seven Springs Mountain Resort in Seven Springs, PA. Visit www.trccc.org for registration, abstract submission, and additional details.
Keynote presentations will be made by two outstanding researchers: Dr. Robert L. Ferris, director of the UPMC Hillman Cancer Center and Hillman Professor of Oncology at the University of Pittsburgh and Dr. Pamela Ohashi, PhD, FRSC, professor in the department of immunology and medical biophysics at the University of Toronto. She also is director of the Immune Therapy Program at Ontario Cancer Institute.
Cancer Institute Director Rich Goldberg, MD; HSC Senior Associate Vice President for Research & Graduate Education and Cancer Institute Deputy Director Laura Gibson, PhD; and Associate Professor of Chemical and Biomedical Engineering and Cancer Institute researcher David Klinke, PhD, are the chairs of the event, which brings together leaders in immunotherapy and other biologic therapies. Patrick Ma, MD, co-leader of the Cancer Institute’s Allen Lung Cancer Program, will present a talk titled Immunotherapies in lung cancer and Dr. Goldberg will present a talk on the extraordinary results of a clinical trial that saved the life of one of his patients at The Ohio State University Comprehensive Cancer Center.
WVU Cancer Institute's Cancer Prevention and Control, in collaboration with the West Virginia Cancer Registry, has released the 2018 Cancer Burden Report. The report provides updated statewide, age-adjusted incidence rates and counts for cancer diagnosed among West Virginia residents from 2011 to 2015.
West Virginia University's Cancer Institute is well-known for its treatment and innovation. Leading the institute is Dr. Richard Goldberg, who has not only established himself as a transformative leader but also a potent researcher and educator.
Brian Boone, M.D., surgical oncologist in the WVU Medicine Department of Surgery and WVU Cancer Institute, performed the state’s first hyperthermic intraperitoneal chemotherapy (HIPEC) infusion. This treatment delivers heated, sterilized chemotherapy to the abdomen as a treatment for cancer that has spread to the lining of the abdominal cavity, or peritoneum.